Aditya Bagrodia

Decipher Prostate is a test for patients with localized prostate cancer that can help personalize treatment. Every patient and their prostate cancer is unique, and Decipher Prostate can provide meaningful insight into the aggressiveness of each individual patient's tumor.

Decipher Prostate is a test for patients with localized prostate cancer that can help personalize treatment. Every patient and their prostate cancer is unique, and Decipher Prostate can provide meaningful insight into the aggressiveness of each individual patient's tumor.

Because the Decipher score is derived solely from the genomic characteristics of the tumor, it provides information not available through already known clinical and pathologic factors. Decipher high-risk patients generally benefit from earlier or intensified treatment, while Decipher low-risk patients may be ideal candidates for monitoring or less overall treatment.

Because the Decipher score is derived solely from the genomic characteristics of the tumor, it provides information not available through already known clinical and pathologic factors. Decipher high-risk patients generally benefit from earlier or intensified treatment, while Decipher low-risk patients may be ideal candidates for monitoring or less overall treatment.

Because the Decipher score is derived solely from the genomic characteristics of the tumor, it provides information not available through already known clinical and pathologic factors. Decipher high-risk patients generally benefit from earlier or intensified treatment, while Decipher low-risk patients may be ideal candidates for monitoring or less overall treatment.

Decipher Prostate is the most validated gene expression test in localized prostate cancer with level one evidence in national clinical practice guidelines and more than 70 peer reviewed publications, including more than 65,000 patients. Visit Verisight.com slash Decipher to learn more. Now back to the show.

Decipher Prostate is the most validated gene expression test in localized prostate cancer with level one evidence in national clinical practice guidelines and more than 70 peer reviewed publications, including more than 65,000 patients. Visit Verisight.com slash Decipher to learn more. Now back to the show.

Decipher Prostate is the most validated gene expression test in localized prostate cancer with level one evidence in national clinical practice guidelines and more than 70 peer reviewed publications, including more than 65,000 patients. Visit Verisight.com slash Decipher to learn more. Now back to the show.

This is Aditya Bagrodia as your host this week, and I'm very excited to introduce back to the show Todd Morgan from University of Michigan, where he heads up the urologic oncology section. Todd, how's it going today?

This is Aditya Bagrodia as your host this week, and I'm very excited to introduce back to the show Todd Morgan from University of Michigan, where he heads up the urologic oncology section. Todd, how's it going today?

This is Aditya Bagrodia as your host this week, and I'm very excited to introduce back to the show Todd Morgan from University of Michigan, where he heads up the urologic oncology section. Todd, how's it going today?

Well, thank you, Todd. Your previous episode on germline testing is still one of my favorites. We actually just published a paper on ordering TENS in men with high-risk prostate cancer. Much of that was inspired by our conversation.

Well, thank you, Todd. Your previous episode on germline testing is still one of my favorites. We actually just published a paper on ordering TENS in men with high-risk prostate cancer. Much of that was inspired by our conversation.

Well, thank you, Todd. Your previous episode on germline testing is still one of my favorites. We actually just published a paper on ordering TENS in men with high-risk prostate cancer. Much of that was inspired by our conversation.

So it's in urologic oncology. And, you know, long and short of it, we got our hands on the Invitae database and indication, who's ordering tests, med-onics, radonics, medical geneticists, and, you know, kind of looked at things over the last... five or seven years. And as maybe would be expected, urologists are getting more familiar with testing.

So it's in urologic oncology. And, you know, long and short of it, we got our hands on the Invitae database and indication, who's ordering tests, med-onics, radonics, medical geneticists, and, you know, kind of looked at things over the last... five or seven years. And as maybe would be expected, urologists are getting more familiar with testing.

So it's in urologic oncology. And, you know, long and short of it, we got our hands on the Invitae database and indication, who's ordering tests, med-onics, radonics, medical geneticists, and, you know, kind of looked at things over the last... five or seven years. And as maybe would be expected, urologists are getting more familiar with testing.

And especially as, you know, the NCCN guidelines has advised for high-risk localized prostate cancer patients to get tested. We're doing more of it, helping out our colleagues kind of down the pike, so to speak. So check it out if you haven't got a chance.

And especially as, you know, the NCCN guidelines has advised for high-risk localized prostate cancer patients to get tested. We're doing more of it, helping out our colleagues kind of down the pike, so to speak. So check it out if you haven't got a chance.

And especially as, you know, the NCCN guidelines has advised for high-risk localized prostate cancer patients to get tested. We're doing more of it, helping out our colleagues kind of down the pike, so to speak. So check it out if you haven't got a chance.